Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study-Reference-Cited by-同舟云学术

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Published:2017-10-19 Issue:16 Volume:130 Page:1800-1808
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Crump Michael¹,Neelapu Sattva S.²,Farooq Umar³,Van Den Neste Eric⁴,Kuruvilla John¹,Westin Jason²,Link Brian K.³,Hay Annette¹,Cerhan James R.⁵,Zhu Liting¹,Boussetta Sami⁴,Feng Lei²,Maurer Matthew J.⁵,Navale Lynn⁶,Wiezorek Jeff⁶,Go William Y.⁶,Gisselbrecht Christian⁴

Affiliation:

1. Canadian Cancer Trials Group, Queen’s University, Kingston, ON, Canada;

2. Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;

3. Division of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA;

4. Lymphoma Academic Research Organization, Pierre-Bénite, France;

5. Department of Health Sciences Research, Mayo Clinic, Rochester, MN; and

6. Kite Pharma, Santa Monica, CA

Abstract

Key Points SCHOLAR-1 is the first patient-level analysis of outcomes of refractory DLBCL from 2 large randomized trials and 2 academic databases. SCHOLAR-1 demonstrated poor outcomes in patients with refractory DLBCL, supporting a need for more effective therapies for these patients.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/16/1800/1402936/blood769620.pdf

Reference37 articles.

1. 2016 US lymphoid malignancy statistics by World Health Organization subtypes [published online ahead of print 12 September 2016];Teras;CA Cancer J Clin

2. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Tilly;Ann Oncol,2012

3. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study;Sant;Lancet Oncol,2014

Cited by 1191 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How can we improve the successful identification of patients suitable for CAR-T cell therapy?;Expert Review of Molecular Diagnostics;2024-09-11

2. Safety and Efficacy of Bispecific Antibodies in Adults with Large B-Cell Lymphomas: A Systematic Review of Clinical Trial Data;International Journal of Molecular Sciences;2024-09-09

3. USP19 exerts a tumor‐promoting role in diffuse large B cell lymphoma through stabilizing PARK7;The FEBS Journal;2024-09-06

4. Follicular lymphoma or diffuse large B-cell lymphoma: a population based analysis of epidemiological and health economic aspects in Germany;2024-09-03

5. Unmet Needs in the First-Line Treatment of Diffuse Large B-cell Lymphoma: Expert Recommendations From the Asia-Pacific Region With a Focus on the Challenging Subtypes;Clinical Lymphoma Myeloma and Leukemia;2024-09